https://european-biotechnology.net/wp-content/uploads/2026/03/Novatis.jpg450940Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-30 07:58:252026-03-30 07:58:25Something of a shopping spree: Novartis to acquire US-based Excellergy for up to $2bn
https://european-biotechnology.net/wp-content/uploads/2026/03/kelli-mcclintock-W3uA3xTRfeA-unsplash-scaled-e1774626079838-1030x580-1.jpg5801030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-30 05:00:542026-03-30 05:00:5410 European Startups to watch in 2026
https://european-biotechnology.net/wp-content/uploads/2026/03/a-chosen-soul-DIFqU-oBCg4-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-26 16:12:082026-03-26 16:12:08TenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancers
https://european-biotechnology.net/wp-content/uploads/2026/03/point-normal-V_VLNr6qtn4-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-25 12:09:542026-03-25 12:09:54Immutrin secures £65m Series A for amyloid-removing heart therapy
https://european-biotechnology.net/wp-content/uploads/2026/03/roche-ihb-_oc_6196_edit-web.jpeg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-25 09:38:182026-03-25 09:38:18Organoids: new Roche research centre in Basel will focus on alternative model systems
